Article

B+L recalls drop

Make sure your patients know about Bausch + Lomb?s voluntary recall of all lots of an eye drop (Soothe Xtra Protection [XP]).

Madison, NJ-Eye-care professionals should alert patients about Bausch + Lomb’s voluntary recall of all lots of an eye drop (Soothe Xtra Protection [XP]).

The company already has contacted retailers and eye-care professionals about the recall. If your patients are using the product, advise them to stop and return the drops to the company. For instructions on returns and reimbursement, patients can call the Soothe Xtra Protection (XP) Hotline, 866/761-9526, or the Bausch + Lomb customer service center, 800/553-5340, which is open 9 a.m. to 5 p.m. ET weekdays.

The company issued the recall after testing showed that the preservative in specific lots (with expiration dates between February 2011 and August 2012) may not be effective for the product’s entire shelf life. Product that is out of specification near the end of shelf life may not adequately protect against inadvertent microbial contamination during storage and usage.

No adverse events have been reported. Potential adverse events include burning, stinging, eye redness, or eye discomfort.

The drop is available only in the United States. The company has alerted the FDA of the recall and is investigating why the specific lots were out of shelf-life specification.

Two other products in the same line (Soothe Preservative Free eye drops and Soothe Night Time Ointment) have not been recalled and remain available to your patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.